Navigation Links
Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
Date:10/1/2007

CEO Glenn A. Oclassen to Join Sleep Experts in Panel Hosted by Natixis

Bleichroeder

PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President and Chief Executive Officer, will participate in a panel focused on middle-of-the-night (MOTN) insomnia at the Natixis Bleichroeder "Hidden Gems" Healthcare Conference.

Date: Monday, October 8, 2007

Panel Discussion: 3:45 p.m. ET

Company Presentation: 4:45 p.m. ET

Location: The Carlton Hotel at 88 Madison Avenue, New York, NY

Mr. Oclassen commented, "This is the first panel sponsored by the investment community to discuss the form of insomnia that is characterized by patients who awaken in the middle of the night and have difficulty returning to sleep. According to a recent survey conducted by the Stanford Sleep Epidemiology Research Center, it is estimated that up to 35% of Americans over the age of 18 suffer primarily from this and related forms of sleep disorder. Despite this large patient population, there is no pharmaceutical agent currently approved to treat this common sleep problem."

"Transcept is developing Intermezzo(TM) (zolpidem tartrate lozenge) for the treatment of such MOTN insomnia. In a recently completed Phase 3 sleep laboratory study, Intermezzo(TM) met the primary endpoint of decreasing sleep onset after a middle of the night awakening, without next day residual effects. I look forward to participating in this panel with these respected sleep experts and raising awareness of this aspect of insomnia."

The MOTN insomnia panel will be co-hosted by Corey Davis, Ph.D., and Jon LeCroy, M.D. of Natixis Bleichroeder. The panel of sleep experts will include Martin B. Scharf, PhD, Director, Center for Research in Sleep Disorders, Cincinnati, Ohio and Gary K. Zammit, Ph.D., Director of the Sleep Disorders Institute at St. Luke's/Roosevelt Hospital, NYC.

Dr. Davis commented, "The potential for the novel claim for MOTN dosing could reduce some of the lingering stigma attached to taking a sleep medication, and perhaps help accelerate growth in the prescription market to a level more consistent with the historical and emerging epidemiological studies that suggest a high prevalence of MOTN insomnia in the US population."

About Intermezzo(TM)

Intermezzo(TM) (zolpidem tartrate lozenge) is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Formulated as a sublingual tablet that dissolves under the tongue, Intermezzo(TM) employs Transcept's Bimucoral(TM) technology to accelerate bioavailability. The company intends to file the Intermezzo(TM) NDA with the US Food and Drug Administration (FDA) in 2008.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the Company's website at: http://www.transcept.com.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Bruker Participates in Dutch Funded Super Microscope Project
4. Venture Investors early-stage fund grows to $115 million
5. Investor warns of angel-venture funding gap
6. Brazilian bio-industry should impress American investors
7. Investors raise $25 million for biodiesel plant
8. Bio-energy and cleantech grab attention of investors
9. Venture Investors to open Michigan office
10. Early-stage executives hear from investors
11. Commerce qualifies seven for investor tax credits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May ... its first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists ... Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most ...
(Date:4/27/2016)... ... 2016 , ... Cambridge Semantics, the leading provider of Smart Data ... has been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of ... serves the needs of end users facing some of the most complex data challenges ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers ... with fingerprint recognition for secure access, voice recognition for hands-free communication, and facial ... are interacting with biometrics technology today. But if they asked Joey Pritikin, ...
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
Breaking Biology Technology:
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
(Date:3/2/2016)... March 2, 2016 ... the "Global Biometrics as a Service ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ... Biometrics as a Service Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ...
(Date:3/1/2016)... 2016  (RSAC Booth #3041) – True fraud costs ... billion is lost to false positives, where good customers ... detection. At the RSA Conference 2016, NuData Security is calling ... authentication by devaluing the data fraudsters have in abundance ... --> --> Cheap and ...
Breaking Biology News(10 mins):